Ranbaxy will need new markets as FDA closes window on U.S., analysts predict

Eric Palmer

What is a generic drugmaker going to do when the FDA finds flies filling its analytics laboratory and shuts down a yet another plant key to serving the market? Start looking for other . That is what say India's generics leader Laboratories is faced with now that it has only one FDA-approved facility to work with and its critical API plant is banned from supplying it.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS